Association between the Proinflammatory Cytokine IL-17F and Helicobacter Pylori Infection in a Sample of Iraqi Patients

SHORT COMMUNICATION
Anas Wisam Malik, Ali Abas Abood, Sarmad Qassim Mohammad

 
International Journal of Biomedicine. 2023;13(2):338-341.
DOI: 10.21103/Article13(2)_ShC
Originally published June 5, 2023

Abstract: 

Background: Infection of the gastric mucosa with Helicobacter pylori (Hp) is characterized by the induction of a number of proinflammatory cytokines, including IL-8, IL-6, and TNF-α, involved in Hp-related gastric inflammation. The functions of members of the IL-17 cytokine family, other than IL-17A, in Hp infection remain understudied. The aim of our study was to assess the association between the proinflammatory cytokine IL-17F and Hp infection in a sample of Iraqi patients.
Methods and Results: This study included 50 Iraqi patients (18 males and 32 females; a mean age of 36±1.74 years) infected with Hp. The healthy control group consisted of 16 subjects (3 males and 13 females), with a mean age of 31±2.44 years. For the qualitative detection of antibodies (IgG, IgM, and IgA) against Hp in the serum, we used the OnSite H. pylori Ab Combo Rapid Test (CTK Biotech). ELISA was used to detect levels of human IL-17F in serum using ABTS ELISA Development Kit (Pepro Tech, USA). The serum level of IL-17F in patients with Hp infection was significantly higher than in the control group (238.9±7.64 pg/mL vs. 114.00±3.66 pg/mL, P=0.0001). However, the serum level of IL-17F in Hp patients was not significantly different between men and women (237±12.12 pg/mL and 239±9.94 pg/mL, respectively, P=0.9015). In addition, no significant difference was found between age subgroups: 240±13.18 pg/mL, 231±10.17 pg/mL, and 252±18.35 pg/mL in age subgroups of <30 years, 30-45 years, and >45 years, respectively, (P>0.05).
Conclusion: Patients infected with Hp were characterized by higher serum levels of IL-17F than non-Hp subjects. IL-17F plays an important role in the inflammatory response to Hp infection in a sample of Iraqi patients.

Keywords: 
Helicobacter pylori • IL-17F • ELISA
References: 
  1. Chen SY, Zhang RG, Duan GC. Pathogenic mechanisms of the oncoprotein CagA in H. pylori-induced gastric cancer (Review). Oncol Rep. 2016 Dec;36(6):3087-3094. doi: 10.3892/or.2016.5145.
  2. Mirzaei S, Keshavarzi F, Karami P. The Prevalence of H. Pylori cagA Gene in Patients with Gastric Ulcer. Iran J Med Microbiol. 2021;15(3):345-351. doi:10.30699/ijmm.15.3.345
  3. Fu HW, Lai YC. The Role of Helicobacter pylori Neutrophil-Activating Protein in the Pathogenesis of H. pylori and Beyond: From a Virulence Factor to Therapeutic Targets and Therapeutic Agents. Int J Mol Sci. 2022 Dec 21;24(1):91. doi: 10.3390/ijms24010091. 
  4. Sruthi MA, Mani G, Ramakrishnan M, Selvaraj J. Dental caries as a source of Helicobacter pylori infection in children: An RT-PCR study. Int J Paediatr Dent. 2023 Jan;33(1):82-88. doi: 10.1111/ipd.13017. 
  5. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007 Jun;56(6):772-81. doi: 10.1136/gut.2006.101634.
  6. Ansari S, Yamaoka Y. Helicobacter pylori Virulence Factors Exploiting Gastric Colonization and its Pathogenicity. Toxins (Basel). 2019 Nov 19;11(11):677. doi: 10.3390/toxins11110677. 
  7. Peek RM Jr, Crabtree JE. Helicobacter infection and gastric neoplasia. J Pathol. 2006 Jan;208(2):233-48. doi: 10.1002/path.1868.
  8. Heidari K, Kaboosi H, Jamali A, Ghaemi EA, Peyravii Ghadikolaii F. Prevalence of Pathogenic Genes cagA and vacA of Helicobacter pylori Isolated in Patients with Digestive disorders from 5 Azar Hospital in Gorgan city in 2017. Iran J Med Microbiol. 2019;13(1):80-88. doi:10.30699/ijmm.13.1.80
  9. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. Schistosomes, liver flukes and Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum. 1994;61:1-241. PMID: 7715068; PMCID: PMC7681621.
  10. Moleiro J, Ferreira S, Lage P, Dias Pereira A. Gastric malt lymphoma: Analysis of a series of consecutive patients over 20 years. United European Gastroenterol J. 2016 Jun;4(3):395-402. doi: 10.1177/2050640615612934.
  11. Elbehiry A, Marzouk E, Aldubaib M, Abalkhail A, Anagreyyah S, Anajirih N, Almuzaini AM, Rawway M, Alfadhel A, Draz A, Abu-Okail A. Helicobacter pylori Infection: Current Status and Future Prospects on Diagnostic, Therapeutic and Control Challenges. Antibiotics (Basel). 2023 Jan 17;12(2):191. doi: 10.3390/antibiotics12020191.
  12. Lu H, Wu JY, Kudo T, Ohno T, Graham DY, Yamaoka Y. Regulation of interleukin-6 promoter activation in gastric epithelial cells infected with Helicobacter pylori. Mol Biol Cell. 2005 Oct;16(10):4954-66. doi: 10.1091/mbc.e05-05-0426. 
  13. Tanahashi T, Kita M, Kodama T, Yamaoka Y, Sawai N, Ohno T, Mitsufuji S, Wei YP, Kashima K, Imanishi J. Cytokine expression and production by purified Helicobacter pylori urease in human gastric epithelial cells. Infect Immun. 2000 Feb;68(2):664-71. doi: 10.1128/IAI.68.2.664-671.2000. 
  14. Tanaka S, Nagashima H, Cruz M, Uchida T, Uotani T, Jiménez Abreu JA, Mahachai V, Vilaichone RK, Ratanachu-Ek T, Tshering L, Graham DY, Yamaoka Y. Interleukin-17C in Human Helicobacter pylori Gastritis. Infect Immun. 2017 Sep 20;85(10):e00389-17. doi: 10.1128/IAI.00389-17. 
  15. Kabir S. The role of interleukin-17 in the Helicobacter pylori induced infection and immunity. Helicobacter. 2011 Feb;16(1):1-8. doi: 10.1111/j.1523-5378.2010.00812.x. 
  16. Bagheri N, Azadegan-Dehkordi F, Shirzad H, Rafieian-Kopaei M, Rahimian G, Razavi A. The biological functions of IL-17 in different clinical expressions of Helicobacter pylori-infection. Microb Pathog. 2015 Apr;81:33-8. doi: 10.1016/j.micpath.2015.03.010.
  17. Caruso R, Fina D, Paoluzi OA, Del Vecchio Blanco G, Stolfi C, Rizzo A, Caprioli F, Sarra M, Andrei F, Fantini MC, MacDonald TT, Pallone F, Monteleone G. IL-23-mediated regulation of IL-17 production in Helicobacter pylori-infected gastric mucosa. Eur J Immunol. 2008 Feb;38(2):470-8. doi: 10.1002/eji.200737635.
  18. McGeachy MJ, Cua DJ, Gaffen SL. The IL-17 Family of Cytokines in Health and Disease. Immunity. 2019 Apr 16;50(4):892-906. doi: 10.1016/j.immuni.2019.03.021. 
  19. Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol. 2009 Aug;9(8):556-67. doi: 10.1038/nri2586. Epub 2009 Jul 3. Erratum in: Nat Rev Immunol. 2009 Oct;9(10):747.
  20. Chang SH, Dong C. IL-17F: regulation, signaling and function in inflammation. Cytokine. 2009 Apr;46(1):7-11. doi: 10.1016/j.cyto.2008.12.024.
  21. Chung SH, Ye XQ, Iwakura Y. Interleukin-17 family members in health and disease. Int Immunol. 2021 Nov 25;33(12):723-729. doi: 10.1093/intimm/dxab075. 
  22. Hymowitz SG, Filvaroff EH, Yin JP, Lee J, Cai L, Risser P, Maruoka M, Mao W, Foster J, Kelley RF, Pan G, Gurney AL, de Vos AM, Starovasnik MA. IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding. EMBO J. 2001 Oct 1;20(19):5332-41. doi: 10.1093/emboj/20.19.5332.
  23. Yang XO, Chang SH, Park H, Nurieva R, Shah B, Acero L, Wang YH, Schluns KS, Broaddus RR, Zhu Z, Dong C. Regulation of inflammatory responses by IL-17F. J Exp Med. 2008 May 12;205(5):1063-75. doi: 10.1084/jem.20071978.
  24. Jin W, Dong C. IL-17 cytokines in immunity and inflammation. Emerg Microbes Infect. 2013 Sep;2(9):e60. doi: 10.1038/emi.2013.58. 
  25. Kawaguchi M, Kokubu F, Odaka M, Watanabe S, Suzuki S, Ieki K, Matsukura S, Kurokawa M, Adachi M, Huang SK. Induction of granulocyte-macrophage colony-stimulating factor by a new cytokine, ML-1 (IL-17F), via Raf I-MEK-ERK pathway. J Allergy Clin Immunol. 2004 Aug;114(2):444-50. doi: 10.1016/j.jaci.2004.03.047.
  26. Kolls JK, Lindén A. Interleukin-17 family members and inflammation. Immunity. 2004 Oct;21(4):467-76. doi: 10.1016/j.immuni.2004.08.018. 
  27. Dixon BREA, Lee TJ, Contreras Healey DC, Li J, Goettel JA, Piazuelo MB, Algood HMS. IL-17 Receptor Signaling through IL-17A or IL-17F Is Sufficient to Maintain Innate Response and Control of Helicobacter pylori Immunopathogenesis. Immunohorizons. 2022 Feb 10;6(2):116-129. doi: 10.4049/immunohorizons.2000072. 
  28. Niu Q, Zhu J, Yu X, Feng T, Ji H, Li Y, Zhang W, Hu B. Immune Response in H. pylori-Associated Gastritis and Gastric Cancer. Gastroenterol Res Pract. 2020 Jan 28;2020:9342563. doi: 10.1155/2020/9342563.
  29. Fraser AG, Scragg R, Metcalf P, McCullough S, Yeates NJ. Prevalence of Helicobacter pylori infection in different ethnic groups in New Zealand children and adults. Aust N Z J Med. 1996 Oct;26(5):646-51. doi: 10.1111/j.1445-5994.1996.tb02934.x.
  30.          Joshi RD, Khadka S, Joshi DM, Kadel A, Dangal G, Dongol Y. Prevalence of helicobacter pylori infection in patients with peptic ulcer disease at Kathmandu Model Hospital. J Chitwan Med Coll. 2018;8(4):3-7.
  31. Luzza F, Parrello T, Monteleone G, Sebkova L, Romano M, Zarrilli R, Imeneo M, Pallone F. Up-regulation of IL-17 is associated with bioactive IL-8 expression in Helicobacter pylori-infected human gastric mucosa. J Immunol. 2000 Nov 1;165(9):5332-7. doi: 10.4049/jimmunol.165.9.5332.
  32. Shi Y, Liu XF, Zhuang Y, Zhang JY, Liu T, Yin Z, Wu C, Mao XH, Jia KR, Wang FJ, Guo H, Flavell RA, Zhao Z, Liu KY, Xiao B, Guo Y, Zhang WJ, Zhou WY, Guo G, Zou QM. Helicobacter pylori-induced Th17 responses modulate Th1 cell responses, benefit bacterial growth, and contribute to pathology in mice. J Immunol. 2010 May 1;184(9):5121-9. doi: 10.4049/jimmunol.0901115. 
  33. Arisawa T, Tahara T, Shibata T, Nagasaka M, Nakamura M, Kamiya Y, Fujita H, Yoshioka D, Arima Y, Okubo M, Hirata I, Nakano H. Genetic polymorphisms of molecules associated with inflammation and immune response in Japanese subjects with functional dyspepsia. Int J Mol Med. 2007 Nov;20(5):717-23.

Download Article
Received March 27, 2023.
Accepted April 30, 2023.
©2023 International Medical Research and Development Corporation.